SCHEMBL4739153

SCHEMBL4739153

COc1ccc(-c2ccc(NC(=O)Nc3ccc(F)c(C(F)(F)F)c3)cc2)c2c(N)onc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 18/20 0.60
FLT3 P36888 15/20 0.60
KIT P10721 11/20 0.60
FLT1 P17948 9/20 0.60
CSF1R P07333 8/20 0.60
LCK P06239 6/20 0.60
LYN P07948 6/20 0.60
FLT4 P35916 6/20 0.60
BLK P51451 6/20 0.60
SRC P12931 4/20 0.60
FYN P06241 4/20 0.60
AURKA O14965 4/20 0.60
ROCK2 O75116 4/20 0.60
RPS6KA5 O75582 4/20 0.60
NTRK1 P04629 4/20 0.60
RET P07949 4/20 0.60
FGFR1 P11362 4/20 0.60
FER P16591 4/20 0.60
RPS6KB1 P23443 4/20 0.60
FRK P42685 4/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5252618 0.91 KDR (0.60) KDRFLT3KITFLT1CSF1R
SCHEMBL1379590 0.90 KDR (0.67) KDRFLT3KITFLT1CSF1R
SCHEMBL1380283 0.88 KDR (0.77) KDRFLT3KITFLT1CSF1R
SCHEMBL424886 0.88 KDR (0.79) KDRFLT3KITFLT1CSF1R
SCHEMBL1383935 0.87 KDR (0.62) KDRFLT3KITFLT1CSF1R
SCHEMBL4736487 0.86 KDR (0.65) KDRFLT3KITFLT1CSF1R
SCHEMBL4735702 0.86 KDR (0.78) KDRFLT3KITFLT1CSF1R
SCHEMBL4738212 0.85 KDR (0.75) KDRFLT3KITFLT1CSF1R
SCHEMBL4735873 0.84 KDR (0.64) KDRFLT3KITFLT1CSF1R
SCHEMBL3394108 0.84 KDR (0.78) KDRFLT3KITFLT1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP disclosed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO disclosed